News

Live Oak Ventures Invests in Innovative Loan Syndication Technology

Live Oak Ventures Invests in Innovative Loan Syndication Technology

Live Oak Ventures Makes a Strategic Investment

Live Oak Ventures, the investment arm of Live Oak Bancshares, Inc., has recently announced its investment in Synply Inc., a cloud technology company focused on improving the loan syndication process for banks. This investment is a reflection of Live Oak's commitment to fostering innovation in the banking sector.

Empowering Banks with the Synply Platform

According to Stephanie Mann, the Chief Strategy Officer at Live Oak Bank, the collaborative and entrepreneurial environment at Live Oak promotes the emergence of promising fintech solutions like Synply. The platform aims to simplify the complexities that banks face when dealing with syndicated loans.

Addressing Industry Pain Points

Corbin Penland, CEO of Synply, brings a wealth of experience from his previous role as managing director of loan syndications at Live Oak Bank. He emphasizes that Synply was developed out of a profound understanding of the challenges faced by banks in the syndication space. The platform allows banks to streamline their workflows, enabling them to focus on building client relationships rather than navigating cumbersome processes.

A Modern Solution

Synply is designed to provide a centralized solution for syndicated lending and portfolio management. By offering a user-friendly interface and robust functionality, it empowers banks to manage the entire loan syndication process, from origination through to servicing—all within a single, efficient platform.

About Live Oak Ventures

Live Oak Ventures is dedicated to investing in fintech-focused companies that enhance the banking industry's capabilities. By targeting innovations that promote open digital solutions, Live Oak Ventures seeks to transform financial services and improve small business banking.

About Synply

As a cloud-based technology firm, Synply is committed to revolutionizing how banks handle loan syndications. By leveraging expertise from seasoned bankers, Synply provides a comprehensive platform that simplifies the complex process of syndication, making it accessible and intuitive for banking institutions.

Contact Information

If you wish to reach out, you can contact Claire Parker, Senior Vice President of Corporate Communications at Live Oak Bank, by phone at 910.597.1592 or via email at claire.parker@liveoak.bank.

Frequently Asked Questions

What is the focus of Live Oak Ventures?

Live Oak Ventures focuses on investing in fintech companies that aim to enhance and innovate the banking industry.

What does the Synply platform offer?

The Synply platform provides tools for banks to streamline the loan syndication and portfolio management process in a user-friendly manner.

Who is Corbin Penland?

Corbin Penland is the CEO of Synply, with extensive previous experience in loan syndications at Live Oak Bank.

How does Synply benefit banks?

Synply helps banks to manage their loan syndication processes more efficiently, allowing them to concentrate on client relationships instead of operational burdens.

How can I get in touch with Live Oak Bank?

You can contact Live Oak Bank's Senior Vice President, Claire Parker, at 910.597.1592 or through email at claire.parker@liveoak.bank.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

illycaffè's B Corp™ Recertification Reflects Bold Commitment

Updated Category News Views 2

illycaffè Hits Milestone with B Corp™ Recertification In an era where corporate responsibility isn't just fodder for feel-good presentations, illycaffè has proven it’s not just paying lip service to the idea. The Italian coffee titan has secured its B Corp™ recertification under snazzier, sharper V2 standards. This isn't just a shiny sticker to slap on marketing...

Continue Reading
Stravito's MCP Server Revolutionizes AI in Business

Updated Category News Views 6

We're seeing another big swing in how enterprises weave AI into the fabric of decision-making. Stravito, an enterprise customer intelligence platform, launched its Model Context Protocol (MCP) Server. This thing brings company-owned research right into the gizmos teams already use. Now, businesses aren't left groping in the dark figuring out their next moves—pretty...

Continue Reading
Clarius Named in TIME's Top HealthTech 2026 Again

Updated Category News Views 6

When a company gets the nod from TIME two years in a row, you know they’re not just tinkering with gadgets—they’re changing the game. Clarius Mobile Health, with its cutting-edge wireless ultrasound tech, has cemented its place in TIME's World's Top HealthTech Companies of 2026. Last I checked, repeating this kind of recognition never comes easy in such a fiercely...

Continue Reading
NORD Honors Innovators Shaping Rare Disease Treatment

Updated Category News Views 5

Saluting the Trailblazers in Rare Disease Space Alright, let's cut to it. In a world flooded with more rare diseases than most of us can count, about 10,000 of them, only a measly 5% have any kind of approved treatment. The National Organization for Rare Disorders (NORD) is out here celebrating the folks who dare to change that bleak outlook. With the 2026 Rare Impact...

Continue Reading
Wrensilva Unveils Studio Console in White Oak

Updated Category News Views 4

The White Oak Revolution Out of San Diego, Wrensilva's giving audiophiles a new reason to tune in: the Studio record console now comes dressed to impress in White Oak. This marks a fresh chapter in their craftsmanship tale, marrying sleek design with the earthy charm of this beloved hardwood. And guess what? The demand for serene home listening setups is peaking like...

Continue Reading
PhoenixAI and Cloudera's Strategic Partnership Shifts Data Landscape

Updated Category News Views 8

Time to Embrace Change: PhoenixAI Teams with Cloudera Mention the word 'partnership' in the tech space, and it's often as common as a cup of joe at dawn—but this one truly shakes things up. We're talking about PhoenixAI hitching its wagon to Cloudera's startup circus, a merging of fire and steel in AI-driven database management. With PhoenixAI strutting its stuff on the...

Continue Reading
VERTESS Tops Axial's 2026 Healthcare M&A Advisor List

Updated Category News Views 5

Strength Takes Top Spot in Healthcare M&A VERTESS has grabbed the gold medal in healthcare sell-side M&A, something that didn't just fall from the sky. Axial gave them the nod as the cream of the crop among the Top 50 Lower Middle Market Healthcare M&A Advisors for 2026. Evaluating the Strengths that Set VERTESS Apart When Axial, that private deal network that's all about...

Continue Reading
Unicycive's Legal Turmoil: Opportunity for Investor Action

Updated Category News Views 4

Unicycive's Legal Headache: What's Brewing? Here we go again, folks. If you're holding shares of Unicycive Therapeutics, Inc. (UNCY), buckle up because it's looking like a storm's on the horizon. The Law Offices of Howard G. Smith have dropped the news that shareholders can step up to lead a securities fraud class action lawsuit against the company. That chance to be part...

Continue Reading
Starr Conspiracy Unveils AI Tool for B2B Tech Firms

Updated Category News Views 5

AI-Driven Insight in Minutes: A Game Changer for B2B Hold onto your hats, because The Starr Conspiracy just lit a fire in the B2B tech world with its latest offering—Battle Card Builder. This free tool cranks out competitive intelligence in no time, literally about four minutes. Geared specifically for B2B tech marketing and sales teams, it combines decades of know-how...

Continue Reading
Alex Jones Returns to Austin: New Studio, New Plans

Updated Category News Views 6

Back in the Saddle: Austin's Controversy Stirs Again It looks like we're seeing a new chapter in a saga that just refuses to end. Alex Jones, the infamous firebrand who's plastered conspiracy theories across the airwaves for two decades, is returning to ground zero in Austin—the old InfoWars studio. After wading through bankruptcy muck and courtroom clashes, Jones is...

Continue Reading

Top 5 Most Recently Viewed Articles

Firstsource Solutions Earns Leadership Status in Lending Services

Updated Category News Views 117

Firstsource Solutions Limited (NSE: FSL) (BSE: 532809) made waves in the lending services sector when it was dubbed a 'Leader' in the 2024 Lending Services Operations PEAK Matrix Assessment by Everest Group. This assessment didn’t just throw around accolades; it rigorously evaluated thirty players in the field based on key metrics like market impact, strategic vision,...

Continue Reading
MoonLake Immunotherapeutics Gains Momentum with FDA Wins

Updated Category News Views 85

Introduction to MoonLake Immunotherapeutics In the current stock market, dominated by discussions on interest rate cuts and the surge in artificial intelligence, the biotechnology sector often gets overshadowed. Nevertheless, for those investors looking to explore beyond the popular tech stocks, clinical-stage biotech companies offer remarkable event-driven returns...

Continue Reading
Adalimumab Market Insights: The Enduring Rise of Humira

Updated Category News Views 63

Exploring Adalimumab Biosimilars in Modern Healthcare The field of adalimumab biosimilars is evolving rapidly, and recent insights reveal a fascinating picture. A study by Spherix Global Insights highlights that AbbVie’s Humira still holds a strong position in the market, even as biosimilars become more prevalent. Survey Findings on Healthcare Provider Attitudes A...

Continue Reading
L'OCCITANE en Provence Launches Unique Boutique on the Upper West Side

Updated Category News Views 115

L'OCCITANE en Provence Unveils Unique Boutique on the Upper West Side L'OCCITANE en Provence has launched a distinctive new boutique that celebrates its roots in the vibrant Upper West Side. Located at 416 Columbus Ave, this boutique features a thoughtful redesign aimed at capturing the essence of Provence, a region in southeastern France that is deeply connected to the...

Continue Reading
How to Find a Mortgage That Fits Your Life and Not Just Your Budget

Updated Category Real Estate Views 68

Many people begin the mortgage process by asking how much they can borrow. That feels logical, but it is usually the wrong starting point. A better question is how much you can carry comfortably without making the rest of your life feel tight every single month. Your mortgage payment is only one part of owning a home. You also need to cover property taxes, utilities, home...

Continue Reading